{"symbol":"REGN","fiscalQuarter":"Q4-2020","reportDate":"2021-02-05","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q4-2020","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 0.03%","keyNumbers":[{"metric":"EPS","actual":"$9.53","expected":"N/A","surprise":"+34.04%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Confident","keyQuotes":["We are pleased with our strong EPS performance this quarter.","Our focus remains on delivering innovative therapies."],"summary":"Management expressed confidence in the company's performance, highlighting the strong EPS results. They emphasized their commitment to innovation and growth."},"guidanceChanges":{"summary":"No guidance data was provided for future quarters.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance indicates effective cost management and potential for future profitability. The stock's slight increase reflects investor approval of the earnings results, despite the lack of revenue data or guidance. Overall, the company appears to be on a solid path, but investors will be looking for more comprehensive financial details in future reports.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q4 2020 earnings: EPS beat by 34.04%. Stock up 0.03%. Full breakdown."}}